GLP-1s are no longer a niche health topic
10.1001/jama.298.2.194 Summary Keywords data mining, FAERS, gastrointestinal adverse events, pharmacovigilance, semaglutide Citation Shu Y, He X, Wu P, Liu Y, Ding Y and Zhang Q (2022) Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Semaglutide is a synthetic GLP-1 receptor agonist analog supplied as a high-purity lyophilized peptide for laboratory research
Always follow the administration instructions provided
This therapy has gained attention for its ability to aid in injury repair, especially in athletes or individuals dealing with joint, muscle, or tendon injuries